Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study)

被引：1

作者：

Uesaka, Katsuhiko

Fukutomi, Akira

Boku, Narikazu

Kanemoto, Hideyuki

Konishi, Masaru

Matsumoto, Ippei

Kaneoka, Yuji

Shimizu, Yasuhiro

Nakamori, Shoji

Sakamoto, Hirohiko

Morinaga, Soichiro

Kainuma, Osamu

Imai, Koji

Sata, Naohiro

Hishinuma, Shoichi

Nakamura, Takayuki

Kanai, Michio

Hirano, Satoshi

Yoshikawa, Yukinobu

Ohashi, Yasuo

机构：

[1] Shizuoka Canc Ctr, Shizuoka, Japan

[2] St Marianna Univ, Sch Med, Kawasaki, Kanagawa, Japan

[3] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[4] Kobe Univ, Grad Sch Med, Kobe, Hyogo 657, Japan

[5] Ogaki Municipal Hosp, Ogaki, Japan

[6] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan

[7] Osaka Natl Hosp, Osaka, Japan

[8] Saitama Canc Ctr, Saitama, Japan

[9] Kanagaw Canc Ctr, Yokohama, Kanagawa, Japan

[10] Chiba Canc Ctr, Chiba 2608717, Japan

[11] Asahikawa Med Univ, Asahikawa, Hokkaido, Japan

[12] Jichi Med Univ, Shimotsuke, Japan

[13] Tochigi Canc Ctr, Utsunomiya, Tochigi, Japan

[14] Gunma Prefectural Canc Ctr, Gunma, Japan

[15] Kasugai Municipal Hosp, Kasugai, Aichi, Japan

[16] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan

[17] Natl Hosp Org Kure Med Ctr, Kure, Japan

[18] Univ Tokyo, Tokyo, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 04期

关键词：

D O I：

10.1200/jco.2013.31.4_suppl.145

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

145

引用

页数：1

共 50 条

[1] Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan adjuvant study group of pancreatic cancer (JASPAC-01)
Maeda, Atsuyuki
Boku, Narikazu
Fukutomi, Akira
Kondo, Satoshi
Kinoshita, Taira
Nagino, Masato
Uesaka, Katsuhiko
[J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (03) : 227 - 229
[2] JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer
Fukutomi, Akira
Uesaka, Katsuhiko
Boku, Narikazu
Kanemoto, Hideyuki
Konishi, Masaru
Matsumoto, Ippei
Kaneoka, Yuji
Shimizu, Yasuhiro
Nakamori, Shoji
Sakamoto, Hirohiko
Morinaga, Soichiro
Kainuma, Osamu
Imai, Koji
Sata, Naohiro
Hishinuma, Shoichi
Nakamura, Takayuki
Kanai, Michio
Hirano, Satoshi
Yoshikawa, Yukinobu
Ohashi, Yasuo
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[3] S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial
Liao, Weiting
Huang, Jiaxing
Zhu, Guiqi
Zhou, Jing
Wen, Feng
Zhang, Pengfei
Zhou, Kexun
Wu, Qiuji
Wang, Xinyuan
Gou, Hongfeng
Li, Qiu
[J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (01) : 133 - 138
[4] Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01)
Hagiwara, Yasuhiro
Ohashi, Yasuo
Uesaka, Katsuhiko
Boku, Narikazu
Fukutomi, Akira
Okamura, Yukiyasu
Konishi, Masaru
Matsumoto, Ippei
Kaneoka, Yuji
Shimizu, Yasuhiro
Nakamori, Shoji
Sakamoto, Hirohiko
Morinaga, Soichiro
Kainuma, Osamu
Imai, Koji
Sata, Naohiro
Hishinuma, Shoichi
Ojima, Hitoshi
Yamaguchi, Ryuzo
Hirano, Satoshi
Sudo, Takeshi
[J]. EUROPEAN JOURNAL OF CANCER, 2018, 93 : 79 - 88
[5] DPD and hENT1 are Not Predictive in Patients with Resected Pancreatic Cancer Treated with Adjuvant S-1 or Gemcitabine Chemotherapy: Collaborative Study of the JASPAC 01 Trial
Okamura, Y.
Yasukawa, S.
Mori, K.
Boku, N.
Akira, F.
Konishi, M.
Morinaga, S.
Toyama, H.
Kaneoka, Y.
Shimizu, Y.
Nakamori, S.
Sata, N.
Kainuma, O.
Kitano, Y.
Sakamoto, H.
Yamaguchi, R.
Hishinuma, S.
Hirano, S.
Yanagisawa, A.
Uesaka, K.
[J]. ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : S134 - S134
[6] Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
Uesaka, Katsuhiko
Boku, Narikazu
Fukutomi, Akira
Okamura, Yukiyasu
Konishi, Masaru
Matsumoto, Ippei
Kaneoka, Yuji
Shimizu, Yasuhiro
Nakamori, Shoji
Sakamoto, Hirohiko
Morinaga, Soichiro
Kainuma, Osamu
Imai, Koji
Sata, Naohiro
Hishinuma, Shoichi
Ojima, Hitoshi
Yamaguchi, Ryuzo
Hirano, Satoshi
Sudo, Takeshi
Ohashi, Yasuo
[J]. LANCET, 2016, 388 (10041): : 248 - 257
[7] Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer
Boku, N.
Uesaka, K.
[J]. EUROPEAN JOURNAL OF CANCER, 2017, 72 : S77 - S77
[8] A randomized phase II trial of adjuvant chemotherapy with S-1 versus S-1 and gemcitabine (GS) versus gemcitabine alone (GEM) in patients with resected pancreatic cancer (CAP-002 study).
Yoshitomi, Hideyuki
Shimizu, Hiroaki
Yoshidome, Hiroyuki
Ohtsuka, Masayuki
Kato, Atsushi
Furukawa, Katsunori
Takayashiki, Tsukasa
Kuboki, Satoshi
Okamura, Daiki
Suzuki, Daisuke
Nakajima, Masayuki
Aida, Toshiaki
Miyazaki, Masaru
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[9] Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancreatic cancer (JASPAC 04)
Toyama, Hirochika
Sugiura, Teiichi
Fukutomi, Akira
Asakura, Hirofumi
Takeda, Yuriko
Yamamoto, Kouji
Hirano, Satoshi
Satoi, Sohei
Matsumoto, Ippei
Takahashi, Shinichiro
Morinaga, Soichiro
Yoshida, Makoto
Sakuma, Yasunaru
Iwamoto, Hidetaka
Shimizu, Yasuhiro
Uesaka, Katsuhiko
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[10] Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancreatic cancer (JASPAC 04)
Sugiura, Teiichi
Toyama, Hirochika
Fukutomi, Akira
Asakura, Hirofumi
Takeda, Yuriko
Yamamoto, Kouji
Hirano, Satoshi
Satoi, Sohei
Matsumoto, Ippei
Takahashi, Shinichiro
Morinaga, Soichiro
Yoshida, Makoto
Sakuma, Yasunaru
Iwamoto, Hidetaka
Shimizu, Yasuhiro
Uesaka, Katsuhiko
[J]. JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2023, 30 (11) : 1249 - 1260

← 1 2 3 4 5 →